Differences

This shows you the differences between two versions of the page.

--- tom_shimabukuro [2022/10/15 16:18]
pamela [Tom Shimabukuro]
+++ tom_shimabukuro [2022/10/15 20:12] (current)
liam
@@ Line 1: / Line 1: @@
-=====  Tom Shimabukuro =====
+======  Tom Shimabukuro ======
-{{ ::tom_shimabukuro_cdc_name_below.png?400|}}
-Dr. Tom Shimabukuro is the deputy director of the Immunization Safety Office at the US Centers for Disease Control and Prevention (CDC). The Immunization Safety Office conducts post-licensure safety monitoring of US vaccines.
-Dr. Shimabukuro has also served as the [[:Vaccine Adverse Event Reporting System]] ([[:VAERS]]) team lead and acting team lead of the [[:Vaccine Safety Datalink]] (VSD) team in the Immunization Safety Office. Prior to coming to the Immunization Safety Office, Dr. Shimabukuro coordinated pandemic influenza planning for CDCâ€™s Immunization Services Division.
+{{ ::tom_shimabukuro_cdc_name_below.png?200|}}
+Dr. **Tom Shimabukuro** is the deputy director of the [[Immunization Safety Office]] at the US [[Centers for Disease Control and Prevention]] (CDC). The Immunization Safety Office conducts post-licensure safety monitoring of US vaccines.
+Dr. Shimabukuro has also served as the [[:Vaccine Adverse Event Reporting System]] (VAERS) team lead and acting team lead of the [[:Vaccine Safety Datalink]] (VSD) team in the Immunization Safety Office. Prior to coming to the Immunization Safety Office, Dr. Shimabukuro coordinated pandemic influenza planning for CDCâ€™s Immunization Services Division.
 He received his medical degree from [[:New York University]]. He did his internship at [[:Emory University]] and preventive medicine residency at the [[:Johns Hopkins University]]. Dr. Shimabukuro also completed a fellowship as an [[:Epidemic Intelligence Service]] Officer at CDC. He is board certified in public health and general preventive medicine. ((https://web.archive.org/web/20201202072226/https://www.eventscribe.com/2018/NFIDFallCVC/ajaxcalls/PresenterInfo.asp?efp=SUhOV09EUVQ0MjE2&PresenterID=491468&rnd=2.500141E-02%20h%0D))
+==== Vaccine Safety Study ====
+Expected Rates of Select Adverse Events following Immunization for COVID-19 Vaccine Safety Monitoring
+{{ ::tom_author_v-safe_studt.png?600|}}
+Winston E Abara, Julianne Gee, Mark Delorey, Ye Tun, Yi Mu, David K Shay, and [[:Tom Shimabukuro]]
+Author information Article notes Copyright and License information Disclaimer
+CDC COVID-19 Response Team, Centers for Disease Control and Prevention Atlanta, Georgia United States
+Corresponding author: Winston Abara; moc.oohay@araba_notsniW
+Alternate author: Julianne Gee; vog.cdc@2gzd; 404-639-1885
+Abstract
+Using meta-analytic methods, we calculated expected rates of 21 potential adverse events of special interest (AESI) that would occur following COVID-19 vaccination within 1-, 7-, and 42-day intervals without causal associations. Based on these expected rates, if 10,000,000 persons are vaccinated, 0.5, 3.7, and 22.5 Guillain-Barre syndrome cases; 0.3, 2.4, and 14.3 myopericarditis cases; and 236.5, 1655.5, and 9932.8 all-cause deaths would occur coincidentally within 1, 7, and 42 days post-vaccination, respectively. Expected rates of potential AESI can contextualize events associated temporally with immunization, aid in safety signal detection, guide COVID-19 vaccine health communications, and inform COVID-19 vaccine benefit-risk assessments. ((https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755334/))
 ==== COVID Vaccine Safety Endorsements ====
 News Release 3-Sep-2021